Phase IIa trial of ibezapolstat is published in Clinical Infectious Diseases as a treatment for clostridium difficile infection.

This publication presents the totality of the ibezapolstat Phase IIa clinical and microbiome data for this antibiotic which appears to possess key properties of an oral antibiotic for CDI ( clostridium Difficile: highly potent against C. difficile; good tolerability; and limited gastrointestinal absorption, resulting in very high fecal concentrations which may reach three orders of magnitude above the MIC for C. difficile. This antimicrobial is a novel DNA polymerase IIIC inhibitor that targets low G+C content gram-positive bacteria with potent activity as demonstrated by the eradication of C. difficile by day three of treatment. The data also show it spares other Firmicutes along with the important Actinobacteria phylum necessary for maintaining a healthy microbiome. These characteristics, in conjunction with ibezapolstat's ability to favorably increase the ratio of secondary-to-primary bile acids in the colon, suggest that ibezapolstat may reduce the likelihood of CDI recurrence when compared to standard of care vancomycin.

See- "Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase IIa Multicenter Clinical Trial "- Kevin W Garey, Jacob McPherson, An Q Dinh, Chenlin Hu, Jinhee Jo et al., Clinical Infectious Diseases, ciac096, https://doi.org/10.1093/cid/ciac096. Published: 04 February 2022.